BRIEF-Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin

* Kamada meets primary endpoint of U.S. Phase 2 study of

inhaled Alpha-1 Antitrypsin for the treatment of Alpha-1

Antitrypsin deficiency

Read more